Evidence suggests that aberrant CCNB1 expression is correlated with unfavorable survival outcomes in various cancers, including ovarian carcinoma, prostate cancer, and lung adenocarcinoma [53–56]. The gene discussed is CCNB1; the disease is Familial prostate cancer.